GnRH Agonist Peptide Modulates Hormone Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to sex hormone levels, such as breast cancer, ovarian cancer, menorrhagia, endometriosis, adenomyosis, uterine fibroids, and infertility, often have side effects and do not effectively modulate hormone secretion to address these conditions.
Innovation Solution
A peptide with an amino acid sequence similar to SEQ ID NO: 1, acting as a GnRH agonist, is used in a pharmaceutical composition to modulate hormone secretion, which includes a peptide with a sequence identity of at least 80% with SEQ ID NO: 1 or its fragments, to treat and prevent diseases related to sex hormone levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for sex hormone level conditions are used, then disease symptoms are addressed, but side effects occur and hormone secretion modulation is insufficient
Solution Approach 1:
The patent changes the chemical structure parameters of existing GnRH agonists by introducing novel molecular scaffolds and substituent groups, resulting in compounds with improved hormone secretion modulation effectiveness and reduced side effects compared to conventional treatments
Solution Approach 2:
The patent creates composite pharmaceutical compositions by combining the novel GnRH agonist compounds with specific excipients and formulation components, enhancing both the effectiveness of hormone secretion modulation and the safety profile by reducing adverse reactions
2Reliability
If peptide composition is used to modulate hormone levels, then treatment effectiveness is improved, but composition stability and safety must be maintained
Solution Approach 1:
The patent optimizes physical and chemical parameters of the peptide composition including pH, ionic strength, and molecular structure of the GnRH agonist, achieving enhanced treatment effectiveness while maintaining composition stability and safety during storage and administration
Solution Approach 2:
The patent develops a peptide composition with controlled stability characteristics that maintains effectiveness during the therapeutic window while preventing long-term stability issues, allowing for safe and effective hormone level modulation
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.